Improving Prognosis Estimation in Lung Cancer
Author Information
Author(s): Schneider P M, Praeuer H W, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher A H, Roth J A
Primary Institution: University of Cologne, Cologne, Germany
Hypothesis
Does multiple molecular marker testing improve the estimation of prognosis in patients with non-small cell lung cancer?
Conclusion
Testing three molecular markers improves prognosis estimation and helps identify low and high-risk groups for treatment failure in lung cancer patients.
Supporting Evidence
- 44.6% of NSCLC patients showed p53 mutations.
- 16.5% of NSCLC patients had c-Ki-ras mutations.
- 54.4% of tumors showed overexpression of c-erbB-2.
- 76.7% of patients were positive for at least one of the three markers.
Takeaway
This study found that checking three specific markers in lung cancer patients helps doctors understand how likely the treatment will work.
Methodology
A prospective study analyzing tumor and normal lung tissue samples for p53, c-Ki-ras, and c-erbB-2 mutations in lung cancer patients.
Participant Demographics
Patients with non-small cell lung cancer in histopathological stages I–IIIA.
Statistical Information
P-Value
P<0.00001
Confidence Interval
82.6% ± 7.9% for low risk, 40.2% ± 5.5% for high risk
Statistical Significance
p<0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website